# NCT02904954 (NCT02904954)

> Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Indication: stage I, II and IIIA NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02904954
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Weill Medical College of Cornell University
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Durvalumab; Durvalumab plus SBRT
- Enrollment: 60
- Primary outcome: Number of Subjects With Major Pathological Response (MPR)

## Indexed commentary on NCT02904954 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02904954